First-line immunotherapy in non-small cell lung cancer: how to select and where to go

Introduction Immunotherapy (IO) has established a new milestone in lung cancer treatment. Several registrational studies have approved immune checkpoint inhibitors (ICIs) in different settings, including the metastatic nonsmall cell lung cancer (NSCLC). As wellknown, responders are just a certain proportion of patients, therefore their selection by using predictive factors has stood out as a crucial issue to address in tailoring a patientcentered care.